Compare Neurocrine Biosciences Inc (NBIX) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs 22nd Century Group Inc — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while 22nd Century Group Inc trades at $2.17 (market cap $1.62M). The key difference: Neurocrine Biosciences Inc is far larger — about 9734.6× 22nd Century Group Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, 22nd Century Group Inc nearer its low. Which is the better fit depends on your goals.
| NBIX | XXII | |
|---|---|---|
Market Cap | $15.77B | $1.62M |
Sector | Health | Technology |
52-Week High | $185.50 | $594.00 |
52-Week Low | $123.10 | $2.13 |
Enterprise Value | $15.78B | -$2.69M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
XXII trades at $2.29, down 4.58% today, showing continued bearish momentum with negative technical signals. The company faces severe financial challenges with negative profit margins (-76.01% net income margin) and consecutive earnings misses. Despite analyst optimism (75% buy ratings), fundamental weakness persists with declining revenue and substantial losses. Recent corporate actions include a 20:1 reverse stock split completed June 2026 to maintain listing compliance.
The outlook remains challenging given persistent operational losses and negative cash flow from operations. Investment opportunity exists if the company can capitalize on its claimed $50B market opportunity and improve gross margins. Key risks include continued cash burn, competitive pressures in tobacco alternatives, and execution challenges in commercializing VLN products.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
